Acetyl%252525252525252520cysteine

# Acetylcysteine ## Overview Acetylcysteine acts as a mucolytic by breaking disulfide bonds in bronchial mucus (reducing viscosity) and as an antidote for acetaminophen (APAP) toxicity by replenishing hepatic glutathione stores. ## Primary Indications * **Acetaminophen toxicity:** Antidote (oral or IV). * **Mucolytic:** Adjunct therapy for abnormal, viscid, or inspissated mucous secretions (e.g., COPD, cystic fibrosis). * **Contrast-induced nephropathy prophylaxis:** (Use is controversial; efficacy is not consistently supported in clinical trials). ## Adult Dosing * **Acetaminophen Toxicity (IV Protocol):** Loading dose 150 mg/kg over 60 min, followed by 50 mg/kg over 4 hours, then 100 mg/kg over 16 hours. *Total duration: 20 hours.* * **Acetaminophen Toxicity (Oral Protocol):** Loading dose 140 mg/kg, followed by 70 mg/kg every 4 hours for 17 doses. * **Mucolytic (Inhalation):** 3–5 mL of 20% solution or 6–10 mL of 10% solution via nebulizer, 3–4 times daily. * **Mucolytic (Instillation):** 1–2 mL of 10%–20% solution every 1–4 hours. ## Pediatric Dosing * **Acetaminophen Toxicity:** Same weight-based dosing as adults. * **Mucolytic (Inhalation):** 3–5 mL of 20% solution or 6–10 mL of 10% solution via nebulizer, 3–4 times daily. * *Note: Dilution with sterile water or saline may be required for infants/young children.* ## Dose Adjustments * **Renal/Hepatic:** No formal dosage adjustments required for mucolytic use. For APAP toxicity, continue the full standard regimen regardless of renal/hepatic clearance status. * **Volume Overload:** In pediatric or fluid-restricted patients, the IV infusion rate/volume must be carefully managed to avoid hyponatremia or fluid overload. ## Contraindications * Hypersensitivity to acetylcysteine or any component of the formulation. * Oral administration is contraindicated in patients with vomiting or GI obstruction (due to aspiration risk). ## Adverse Effects * **IV/Systemic:** Anaphylactoid reactions (flushing, rash, hypotension, angioedema), especially with the loading dose. * **Inhalation:** Bronchospasm (more common in asthmatics), stomatitis, rhinorrhea, hemoptysis. * **GI:** Nausea/vomiting (common with oral administration). ## Key Drug Interactions * **Activated Charcoal:** May bind with oral acetylcysteine. Administer charcoal at least 1 hour prior to acetylcysteine or clarify institutional protocol regarding charcoal removal. * **Drug Incompatibility:** Acetylcysteine is physically incompatible with certain antibiotics (e.g., ampicillin, tetracyclines, erythromycin) if mixed in the same nebulizer solution. ## Monitoring * **APAP Toxicity:** Serum APAP levels, ALT/AST, INR, creatinine, and electrolytes. * **Anaphylactoid Reaction:** Monitor closely during the initial IV bolus; stop infusion and treat with antihistamines, fluids, or epinephrine if reaction occurs. * **Respiratory:** Monitor for bronchospasm, especially in patients with hyperreactive airway disease. ## Clinical Pearls * **Odor:** The drug has a strong, "rotten egg" (sulfur) odor, which may cause nausea. * **Nebulization:** If using a face mask for inhalation, a sticky residue may form on the face; wash with water after treatment. * **Protocol Dependency:** IV APAP protocols vary by institution; always consult local toxicology guidelines or the hospital’s specific infusion protocol. * **Asthma:** When used as a mucolytic in patients with asthma, pretreatment with a bronchodilator is often recommended to prevent drug-induced bronchospasm. *** **Educational Disclaimer:** This information is for educational purposes only. Clinical practice guidelines and local hospital protocols may vary significantly. Always verify current prescribing information, institutional dosage calculators, and patient-specific factors with a clinical pharmacist or the latest drug reference databases (e.g., Lexicomp, Micromedex) before prescribing or administering.